Printer Friendly

UPJOHN ANNOUNCES NEW ANIMAL DRUG CLEARANCES

 UPJOHN ANNOUNCES NEW ANIMAL DRUG CLEARANCES
 KALAMAZOO, Mich., Aug. 18 /PRNewswire/ -- The Upjohn Company


(NYSE: UPJ) today announced that it is introducing Naxcel Sterile Powder for use in swine and day-old chicks.
 The two separate clearances for Naxcel are for treatment of swine respiratory disease (pneumonia), and early chick mortality. The product is effective in treating bacterial pneumonia caused by four major infectious pathogens in swine, and in treating day-old chicks for colibacillosis associated with Escherichia coli.
 A cepholasporin antibiotic, Naxcel was approved in 1988 to treat respiratory disease in beef cattle, and in 1991 for use in lactating dairy cattle.
 Worldwide swine industry estimates place annual losses to swine pneumonia in excess of $2 billion, while the poultry market loses an estimated $22 million to early chick mortality.
 According to Thomas G. Schalk, D.V.M., Upjohn corporate vice president for worldwide animal health, Naxcel was approved with zero pre-slaughter withdrawal in swine.
 "Naxcel's safety package has been well-documented throughout its development and today represents a model product of The Upjohn Company in terms of ensuring food safety," Schalk says. "Its zero pre-slaughter withdrawal for swine follows approval with zero withdrawal in beef cattle and no milk discard when administered to lactating dairy cattle."
 Naxcel is sold by Upjohn through veterinarians only.
 The Upjohn Company is a worldwide, research-based provider of human health care products, animal health products, agronomic and vegetable seeds and specialty chemicals. Headquartered in Kalamazoo, the company has been dedicated to improving health and nutrition for more than a century.
 -0- 8/18/92
 /CONTACT: Joseph Burkett of Upjohn Public Relations, 616-385-6693/
 (UPJ) CO: The Upjohn Company ST: Michigan IN: MTC SU: PDT


ML -- DE005 -- 0885 08/18/92 10:48 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Aug 18, 1992
Words:286
Previous Article:HEALTH EQUITY PROPERTIES REDUCES DEBT
Next Article:WANG LABORATORIES FILES UNDER CHAPTER 11; REPORTS FOURTH QUARTER, FISCAL YEAR RESULTS; NOON NEWS CONFERENCE IN CAMBRIDGE, MASS.
Topics:


Related Articles
UPJOHN TO INTRODUCE NEW LACTATING COW MASTITIS TREATMENT
UPJOHN ANTIBIOTIC CLEARED FOR USE IN HORSES
UPJOHN ANNOUNCES NAXCEL CLEARED FOR USE IN DOGS
UPJOHN TO ACQUIRE PARKE-DAVIS VETERINARY BUSINESS
UPJOHN ANNOUNCES JOINT VENTURE IN CHINA
ROUTINE DENTAL CARE CAN ADD YEARS TO PET'S LIFE
Pharmacia & Upjohn Acquires Pherrovet AB
Bayer Purchases Animal Health Biological Assets from Pharmacia & Upjohn
Atrix Laboratories Reports 1997 First Quarter Results
Pharmacia & Upjohn Dedicates New Manufacturing Plant in China

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters